ANIKA THERAPEUTICS INC (ANIK) Fundamental Analysis & Valuation

NASDAQ:ANIK • US0352551081

Current stock price

14.2 USD
-0.1 (-0.7%)
At close:
14.2 USD
0 (0%)
After Hours:

This ANIK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ANIK Profitability Analysis

1.1 Basic Checks

  • In the past year ANIK has reported negative net income.
  • ANIK had a positive operating cash flow in the past year.
  • ANIK had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: ANIK reported negative operating cash flow in multiple years.
ANIK Yearly Net Income VS EBIT VS OCF VS FCFANIK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

  • ANIK's Return On Assets of -17.44% is fine compared to the rest of the industry. ANIK outperforms 77.84% of its industry peers.
  • The Return On Equity of ANIK (-22.50%) is better than 80.15% of its industry peers.
Industry RankSector Rank
ROA -17.44%
ROE -22.5%
ROIC N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ANIK Yearly ROA, ROE, ROICANIK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

  • ANIK has a better Gross Margin (54.74%) than 76.69% of its industry peers.
  • ANIK's Gross Margin has declined in the last couple of years.
  • ANIK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
ANIK Yearly Profit, Operating, Gross MarginsANIK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ANIK Health Analysis

2.1 Basic Checks

  • ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANIK Yearly Shares OutstandingANIK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANIK Yearly Total Debt VS Total AssetsANIK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • ANIK has an Altman-Z score of 4.25. This indicates that ANIK is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.25, ANIK is in the better half of the industry, outperforming 70.33% of the companies in the same industry.
  • ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.25
ROIC/WACCN/A
WACC8.92%
ANIK Yearly LT Debt VS Equity VS FCFANIK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 5.32 indicates that ANIK has no problem at all paying its short term obligations.
  • ANIK has a Current ratio of 5.32. This is comparable to the rest of the industry: ANIK outperforms 58.57% of its industry peers.
  • ANIK has a Quick Ratio of 4.47. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 4.47, ANIK perfoms like the industry average, outperforming 53.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.32
Quick Ratio 4.47
ANIK Yearly Current Assets VS Current LiabilitesANIK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. ANIK Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 63.29% over the past year.
EPS 1Y (TTM)63.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.04%

3.2 Future

  • ANIK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.08% yearly.
  • ANIK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.10% yearly.
EPS Next Y50.34%
EPS Next 2Y35.36%
EPS Next 3Y20.08%
EPS Next 5YN/A
Revenue Next Year5.57%
Revenue Next 2Y6.49%
Revenue Next 3Y6.1%
Revenue Next 5YN/A

3.3 Evolution

ANIK Yearly Revenue VS EstimatesANIK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
ANIK Yearly EPS VS EstimatesANIK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

2

4. ANIK Valuation Analysis

4.1 Price/Earnings Ratio

  • ANIK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANIK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIK Price Earnings VS Forward Price EarningsANIK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

  • 90.56% of the companies in the same industry are more expensive than ANIK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 315.99
EV/EBITDA N/A
ANIK Per share dataANIK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ANIK's earnings are expected to grow with 20.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.36%
EPS Next 3Y20.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ANIK Dividend Analysis

5.1 Amount

  • No dividends for ANIK!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANIK Fundamentals: All Metrics, Ratios and Statistics

ANIKA THERAPEUTICS INC

NASDAQ:ANIK (3/13/2026, 8:09:50 PM)

After market: 14.2 0 (0%)

14.2

-0.1 (-0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners86.01%
Inst Owner Change1.25%
Ins Owners3.88%
Ins Owner Change1.28%
Market Cap204.76M
Revenue(TTM)N/A
Net Income(TTM)-33.04M
Analysts85
Price Target16.32 (14.93%)
Short Float %5.54%
Short Ratio4.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.77%
Min EPS beat(2)-8.36%
Max EPS beat(2)41.9%
EPS beat(4)1
Avg EPS beat(4)-124.38%
Min EPS beat(4)-398.5%
Max EPS beat(4)41.9%
EPS beat(8)1
Avg EPS beat(8)-464.53%
EPS beat(12)2
Avg EPS beat(12)-316.32%
EPS beat(16)5
Avg EPS beat(16)-234.39%
Revenue beat(2)1
Avg Revenue beat(2)0.22%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)2.34%
Revenue beat(4)2
Avg Revenue beat(4)-1.17%
Min Revenue beat(4)-8.59%
Max Revenue beat(4)3.46%
Revenue beat(8)4
Avg Revenue beat(8)-1.69%
Revenue beat(12)7
Avg Revenue beat(12)0.21%
Revenue beat(16)11
Avg Revenue beat(16)1.82%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.82
P/FCF 315.99
P/OCF 25.18
P/B 1.39
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)0.04
FCFY0.32%
OCF(TTM)0.56
OCFY3.97%
SpS7.82
BVpS10.18
TBVpS9.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.44%
ROE -22.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.74%
FCFM 0.57%
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 120.28%
Cap/Sales 6.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.32
Quick Ratio 4.47
Altman-Z 4.25
F-Score5
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)64.17%
Cap/Depr(5y)48.11%
Cap/Sales(3y)5.41%
Cap/Sales(5y)4.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.33%
EPS Next Y50.34%
EPS Next 2Y35.36%
EPS Next 3Y20.08%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.04%
Revenue Next Year5.57%
Revenue Next 2Y6.49%
Revenue Next 3Y6.1%
Revenue Next 5YN/A
EBIT growth 1Y-101.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.73%
EBIT Next 3Y33.42%
EBIT Next 5Y24.64%
FCF growth 1Y105.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y264.3%
OCF growth 3Y-13.68%
OCF growth 5Y-31.94%

ANIKA THERAPEUTICS INC / ANIK Fundamental Analysis FAQ

What is the fundamental rating for ANIK stock?

ChartMill assigns a fundamental rating of 3 / 10 to ANIK.


What is the valuation status of ANIKA THERAPEUTICS INC (ANIK) stock?

ChartMill assigns a valuation rating of 2 / 10 to ANIKA THERAPEUTICS INC (ANIK). This can be considered as Overvalued.


Can you provide the profitability details for ANIKA THERAPEUTICS INC?

ANIKA THERAPEUTICS INC (ANIK) has a profitability rating of 2 / 10.


Can you provide the financial health for ANIK stock?

The financial health rating of ANIKA THERAPEUTICS INC (ANIK) is 7 / 10.


Can you provide the expected EPS growth for ANIK stock?

The Earnings per Share (EPS) of ANIKA THERAPEUTICS INC (ANIK) is expected to grow by 50.34% in the next year.